Idiopathic Pulmonary Fibrosis: HRCT UIP Diagnosis and Antifibrotic Therapy
ATS/ERS/JRS/ALAT 2022 framework for IPF diagnosis using high-resolution CT UIP pattern, evidence-based use of nintedanib and pirfenidone antifibrotics, acute exacerbation management, and lung transplant referral.
Executive Summary
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause occurring primarily in older adults (median age 65–70), characterized by the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The 2022 ATS/ERS/JRS/ALAT guideline allows confident diagnosis without surgical lung biopsy when high-resolution CT shows the typical UIP pattern in the appropriate clinical context (age over 60, exclusion of identifiable causes). Two antifibrotic therapies — nintedanib 150 mg PO BID and pirfenidone 801 mg PO TID — slow the decline in forced vital capacity (FVC) by approximately 50% over 52 weeks and are recommended at diagnosis regardless of severity. Comprehensive care includes early lung transplant referral (median survival without transplant 3–5 years; 5-year post-transplant survival 50–55%), pulmonary rehabilitation, supplemental oxygen, treatment of comorbid pulmonary hypertension and GERD, vaccination, and palliative symptom management. Acute exacerbation of IPF (AE-IPF) carries 50–90% in-hospital mortality and requires high-dose corticosteroids, broad-spectrum antibiotics, and urgent transplant consideration.
S1. Pathogenesis, Epidemiology, and Risk Factors
Genetic and Environmental Risk Factors
Idiopathic pulmonary fibrosis affects an estimated 8–14 per 100,000 adults annually in North America and Europe, with prevalence rising as the population ages and diagnostic awareness improves. The disease shows a strong age dependency (median diagnosis age 65–70, rare under age 50), male predominance (1.5–2:1), and association with cigarette smoking (>20 pack-year exposure raises risk 3-fold). Despite the “idiopathic” designation, multiple risk factors are well-established: chronic microaspiration from gastroesophageal reflux disease, occupational dust exposures (metal, wood, stone), and viral infection (EBV, CMV) have all been linked epidemiologically.
Genetic susceptibility plays a significant role. Common variants in the MUC5B promoter (rs35705950 minor allele) are present in approximately 35% of IPF patients versus 9% of controls and confer a 6-fold increased risk per allele copy. Familial pulmonary fibrosis (≥2 affected first-degree relatives) accounts for 10–20% of cases and is associated with rare variants in telomere-related genes (TERT, TERC, RTEL1, PARN) and surfactant protein genes (SFTPC, SFTPA2). Telomere shortening — measured by leukocyte telomere length below the 10th percentile — is found in 20–25% of sporadic IPF cases and predicts faster lung function decline, worse transplant outcomes, and risk of bone marrow failure.
Aberrant Wound Healing — Current Pathogenic Model
The prevailing pathogenic model of IPF is repeated alveolar epithelial injury in a genetically susceptible host with impaired re-epithelialization, leading to aberrant fibroblast and myofibroblast activation, excessive extracellular matrix deposition, and progressive architectural distortion. Type II alveolar epithelial cells (AT2) — the lung’s stem cell population for alveolar regeneration — show endoplasmic reticulum stress, telomere dysfunction, and senescence in IPF. Failed AT2 differentiation into AT1 cells leads to formation of bronchiolar-like cells in distal airspaces (the histologic correlate of “bronchiolization” and honeycomb cyst formation).
Activated myofibroblasts congregate in fibroblastic foci — the pathognomonic histologic feature of UIP — and secrete collagen and TGF-β, sustaining the pro-fibrotic loop. Both nintedanib (a tyrosine kinase inhibitor blocking PDGFR, FGFR, and VEGFR signaling) and pirfenidone (an antifibrotic with TGF-β-modulating and antioxidant properties) interrupt this pathway and form the foundation of current pharmacotherapy.
| Risk Factor | Estimated Risk Increase | Clinical Implication |
|---|---|---|
| Age >60 | Strongest demographic factor | Always consider IPF in older smokers with dyspnea |
| Male sex | 1.5–2× over female | Lower threshold to obtain HRCT |
| Smoking ≥20 pack-years | 3× risk | Smoking cessation essential at diagnosis |
| MUC5B rs35705950 minor allele | 6× per allele copy | Genetic testing not routine but emerging in research |
| Telomere shortening (<10th percentile) | Faster decline, worse transplant outcomes | Avoid mycophenolate post-transplant in TERT/TERC carriers |
| Familial fibrosis (≥2 relatives) | 10–20% of all IPF cases | Genetic counseling, family screening |
| Chronic GERD/microaspiration | 2–3× risk | PPI even if asymptomatic per guidelines |
| Occupational dust (metal, wood, stone) | 1.5–2× risk | Detailed occupational history mandatory |
S2. Diagnosis: HRCT UIP Pattern Classification (ATS/ERS 2022)
The Four HRCT Patterns — Definite UIP, Probable UIP, Indeterminate, Alternative
The 2022 ATS/ERS/JRS/ALAT clinical practice guideline classifies HRCT findings into four patterns that determine the need for tissue confirmation and the diagnostic confidence level. Definite UIP requires all four features: subpleural and basal predominance (often heterogeneous distribution), reticular abnormality, honeycombing with or without traction bronchiectasis or bronchiolectasis, and absence of features suggesting alternative diagnosis. When HRCT shows definite UIP in a patient over age 60 without identifiable cause of interstitial lung disease (no significant occupational/environmental exposure, no connective tissue disease, no offending drug), surgical lung biopsy is unnecessary and IPF can be diagnosed with high confidence.
Probable UIP shows subpleural and basal predominant reticular abnormality with traction bronchiectasis or bronchiolectasis but lacks honeycombing. Indeterminate for UIP shows subpleural basal predominance of subtle reticulation with or without mild ground-glass opacity that may suggest non-UIP pattern. Alternative diagnosis shows features suggesting NSIP (predominant ground-glass), hypersensitivity pneumonitis (mosaic attenuation, three-density sign, peribronchovascular distribution), sarcoidosis (perilymphatic micronodules, hilar adenopathy), or other specific etiologies. The latter three patterns require multidisciplinary discussion (MDD) and often tissue sampling.
| HRCT Pattern | Diagnostic Features | Tissue Required? | Diagnostic Confidence |
|---|---|---|---|
| Definite UIP | Subpleural/basal + reticular + honeycombing + no inconsistent features | No (in appropriate clinical context) | ~95% specificity |
| Probable UIP | Subpleural/basal + reticular + traction bronchiectasis (no honeycombing) | Consider; many cases biopsy can be avoided in age >60 | ~85% specificity |
| Indeterminate for UIP | Subpleural basal subtle reticulation +/− mild GGO | Yes — TBLC or SLB recommended | Cannot exclude alternative |
| Alternative diagnosis | Predominant GGO, mosaic, peribronchovascular, perilymphatic, etc. | Yes — workup for HP, NSIP, sarcoidosis, CTD-ILD | UIP unlikely |
Multidisciplinary Discussion (MDD) and Tissue Sampling
Multidisciplinary discussion involving pulmonologist, thoracic radiologist, and pathologist is the diagnostic gold standard for ILD and is recommended for all cases of indeterminate or alternative HRCT patterns. MDD improves diagnostic accuracy by 15–25% over individual specialist assessment and ensures concordance between clinical, radiologic, and pathologic findings. Patients should be referred to ILD centers when local MDD is not available.
Tissue sampling options include transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB). TBLC, performed via flexible bronchoscopy with cryoprobe sampling under fluoroscopic guidance, provides specimens of 5–10 mm with diagnostic yield comparable to SLB (80–85% concordance) at lower morbidity (mortality <1% versus 2–4% for SLB) and is now preferred at experienced centers. SLB via video-assisted thoracoscopic surgery (VATS) remains the gold standard when TBLC is unavailable or unrevealing. Bronchoalveolar lavage may be useful to exclude hypersensitivity pneumonitis (lymphocytosis >30% supports HP over IPF) and infection.
Diagnostic workup for IPF includes: comprehensive serology to exclude connective tissue disease (ANA, RF, anti-CCP, ANCA, myositis panel including anti-synthetase antibodies, scleroderma panel), occupational/environmental history (especially birds, molds, hot tubs, occupational dusts), drug review (amiodarone, methotrexate, nitrofurantoin), pulmonary function tests (FVC, FEV1, DLCO, 6-minute walk distance with continuous SpO₂), and screening for pulmonary hypertension (echocardiogram).
📋 Required workup before confirming IPF diagnosis
- HRCT chest: 1mm slices, prone images, expiratory phase to assess air trapping
- Pulmonary function: FVC, FEV1, FEV1/FVC, TLC, DLCO; 6-minute walk distance with continuous SpO₂
- Serology to exclude CTD-ILD: ANA + titer + pattern, RF, anti-CCP, ANCA, myositis panel (anti-Jo-1, anti-MDA5, anti-PL-7), scleroderma (anti-Scl-70, anti-centromere), Sjögren (anti-SSA/SSB)
- Detailed exposure history: Birds (current/past), feather pillows/duvets, molds, hot tubs, occupational dusts (sandblasting, mining, woodworking, textile)
- Drug review: Amiodarone, methotrexate, nitrofurantoin, bleomycin, immune checkpoint inhibitors
- Echocardiography: RVSP, TAPSE; refer for RHC if mPAP suspected >25 mmHg
- BAL (if indeterminate HRCT): Lymphocytosis >30% suggests HP, >15% suggests sarcoid, neutrophil predominance compatible with IPF
S3. Antifibrotic Therapy: Nintedanib and Pirfenidone
Indications, Drug Selection, and Initiation
Both nintedanib and pirfenidone are recommended in the 2015 ATS/ERS/JRS/ALAT guideline for treatment of all patients with IPF regardless of FVC severity. The INPULSIS-1 and INPULSIS-2 trials of nintedanib and the ASCEND and CAPACITY trials of pirfenidone both demonstrated approximately 50% reduction in annual FVC decline (from approximately 240 mL/year to 110–130 mL/year), reduced acute exacerbation risk (nintedanib), and trends toward mortality benefit. Subgroup analyses have shown benefit across age (≥75 included), sex, baseline FVC, smoking status, and disease severity, supporting universal recommendation at diagnosis.
Nintedanib is dosed at 150 mg PO BID with food. Consider dose reduction to 100 mg BID for hepatotoxicity (LFTs ≥3× ULN), severe diarrhea uncontrolled with anti-diarrheal therapy, or significant weight loss. Pirfenidone is started at 267 mg PO TID with meals × 7 days, then 534 mg PO TID × 7 days, then 801 mg PO TID as maintenance. The titration improves tolerability of GI side effects. No head-to-head trial has demonstrated superiority of one drug over the other; choice is individualized by side effect profile, drug interactions, comorbidities, and patient preference.
| Feature | Nintedanib (Ofev) | Pirfenidone (Esbriet) |
|---|---|---|
| Mechanism | Tyrosine kinase inhibitor (PDGFR, FGFR, VEGFR) | TGF-β modulator + antioxidant |
| Dose (maintenance) | 150 mg PO BID with food | 801 mg PO TID with meals (after titration) |
| FVC decline reduction | ~50% over 52 weeks | ~50% over 52 weeks |
| Major side effects | Diarrhea (62%), nausea (24%), hepatotoxicity (5%) | Photosensitivity (28%), nausea (36%), rash (30%), elevated LFTs |
| Hepatic contraindication | Avoid in Child-Pugh B/C | Avoid in Child-Pugh C; caution in B |
| Drug interactions | Avoid strong CYP3A4 inducers; caution P-gp inhibitors | Avoid CYP1A2 inhibitors (fluvoxamine), strong inducers |
| Bleeding risk | Caution with anticoagulants (VEGFR inhibition) | Minimal |
| Cardiovascular | Caution with recent MI; QT prolongation possible | QT prolongation possible |
| Lab monitoring | LFTs at baseline, monthly × 3, then q3 months | LFTs at baseline, monthly × 6, then q3 months |
| Cost (US, monthly) | ~$10,000 | ~$10,000 |
Side Effect Management — Keep Patients on Therapy
Discontinuation of antifibrotic therapy due to side effects is common (15–25% in clinical trials, higher in real-world practice). Proactive symptom management is essential to maintain disease-modifying therapy. For nintedanib-induced diarrhea: start loperamide 2–4 mg PO PRN at onset, instruct patients to take medication with substantial meals, and consider dose reduction to 100 mg BID before discontinuation. Persistent diarrhea may respond to cholestyramine 4 g BID or octreotide if severe. For pirfenidone photosensitivity: rigorous sunscreen (broad-spectrum SPF 50+, applied every 2 hours), protective clothing, and avoidance of direct sun exposure 11 AM to 3 PM; rash typically responds to topical corticosteroids and antihistamines.
For nausea (both drugs): take with substantial meals (not just snacks), consider ondansetron 4–8 mg PO BID-TID PRN, prochlorperazine 10 mg PO TID PRN. For hepatotoxicity: hold drug if AST/ALT >3× ULN with symptoms or >5× ULN regardless; monitor weekly until normalized; restart at reduced dose. Dose reduction below standard maintenance is acceptable to preserve some antifibrotic benefit; complete discontinuation should be a last resort.
⚠️ Antifibrotic monitoring schedule
- Baseline: CBC, CMP including bilirubin and LFTs, pregnancy test (women of childbearing age — both drugs Category D/X)
- Monthly × first 3 months (nintedanib) or × 6 months (pirfenidone): LFTs (AST, ALT, total bilirubin)
- Every 3 months thereafter: LFTs, weight, FVC measurement
- Every 6 months: 6-minute walk test with SpO₂, DLCO if available
- Annually: HRCT chest (assess for honeycomb progression, lung cancer surveillance)
- Hold drug if: AST/ALT >5× ULN, AST/ALT >3× ULN with symptoms, severe persistent diarrhea, severe photosensitivity reaction
Combination antifibrotic therapy (nintedanib + pirfenidone) has been studied in small trials and is biologically plausible given non-overlapping mechanisms but is not currently recommended outside research settings due to cost, additive toxicity, and absence of demonstrated mortality benefit. Switch therapy (nintedanib to pirfenidone or vice versa) is appropriate for intolerance and produces FVC stabilization in many patients.
S4. Comorbidity Management and Supportive Care
Optimal IPF care extends well beyond antifibrotics to address the multiple comorbidities that drive symptom burden, hospitalization, and mortality. Screening and management of these comorbidities is a quality-of-care indicator at ILD centers.
| Comorbidity | Prevalence in IPF | Screening | Management |
|---|---|---|---|
| Pulmonary hypertension | 30–50% in advanced disease | Echo annually; RHC if mPAP >25 suspected | Treat hypoxemia; consider inhaled treprostinil (INCREASE trial) |
| GERD | 67–90% (often silent) | Symptom inquiry; 24h pH probe if uncertain | PPI even if asymptomatic (per 2015 guideline conditional rec) |
| Obstructive sleep apnea | 60–90% | STOP-BANG, polysomnography | CPAP improves sleep symptoms; uncertain effect on IPF progression |
| Coronary artery disease | 20–60% | Cardiac stress testing if symptomatic | Standard CAD management; avoid β-blockers if pulmonary HTN |
| Lung cancer | 10× general population risk | Annual HRCT chest | Multidisciplinary tumor board; surgery often contraindicated |
| Depression/anxiety | 25–50% | PHQ-9, GAD-7 routinely | SSRI, CBT, palliative care referral |
| Venous thromboembolism | Increased risk; 2–3× general | Heightened suspicion in acute decline | Standard prophylaxis when hospitalized |
| Emphysema (CPFE) | 30–35% (smokers) | HRCT, PFTs (preserved FVC, low DLCO) | Combined approach; worse prognosis with PH |
Pulmonary rehabilitation improves exercise capacity, dyspnea, quality of life, and mood in IPF patients across the disease severity spectrum. The standard 8–12 week program includes supervised exercise training, education, breathing techniques, and energy conservation strategies. Benefits typically wane within 6 months of program completion, supporting maintenance programs or repeat enrollment. Refer all symptomatic IPF patients (mMRC dyspnea ≥1).
Supplemental oxygen is recommended for resting hypoxemia (SpO₂ ≤88% on room air) and exertional desaturation (SpO₂ <88% on 6-minute walk). Ambulatory oxygen titrated to maintain SpO₂ ≥90% during activity improves walking distance and quality of life. High-flow nasal cannula at home can support patients with progressive hypoxemia who require flows beyond standard concentrators.
Vaccinations: annual influenza vaccine, pneumococcal vaccines (PCV13/PCV20 followed by PPSV23 per current recommendations), COVID-19 vaccination per current guidance, and Tdap booster every 10 years. RSV vaccine is now recommended for adults aged ≥60 with chronic lung disease.
Pulmonary Hypertension Co-management
Group 3 pulmonary hypertension (PH due to lung disease) develops in roughly 30-50 percent of advanced IPF and substantially worsens prognosis. The 2022 ATS/ERS/JRS/ALAT guideline acknowledges a limited role for inhaled treprostinil in selected patients with PH-ILD based on the INCREASE trial, but oral pulmonary vasodilators (sildenafil, ambrisentan, riociguat) have shown harm or no benefit in this population and should not be used outside trial settings. Screening with echocardiography is recommended for any patient with disproportionate dyspnea, desaturation on six-minute walk, or DLCO disproportionately low compared with FVC. Right heart catheterization should be considered before initiating any PH-directed therapy or in patients being evaluated for lung transplantation.
Nutrition, Reflux, and Cough Management
Weight loss is common in advanced IPF and is associated with worse outcomes independent of FVC. Nutritional assessment and early referral to a dietitian, with anabolic strategies tailored to the patient’s exercise capacity, should be part of routine care. Gastroesophageal reflux is highly prevalent and is the focus of ongoing debate regarding causation versus association; routine PPI therapy is reasonable in symptomatic patients but should not be assumed to alter disease trajectory. Chronic cough is one of the most distressing symptoms and may respond to low-dose opioids (morphine 5-10 mg twice daily), gabapentin or pregabalin, or speech therapy techniques in selected patients; routine cough suppressants are usually inadequate.
S5. Acute Exacerbation, Lung Transplant Referral, and End-of-Life Care
Acute Exacerbation of IPF (AE-IPF)
AE-IPF is defined by the 2016 ATS Working Group as: (1) prior or concurrent IPF diagnosis, (2) acute worsening or development of dyspnea typically <1 month duration, (3) HRCT showing new bilateral ground-glass opacity and/or consolidation superimposed on a UIP pattern, (4) deterioration not fully explained by cardiac failure or fluid overload. Identifiable triggers (infection, aspiration, drug toxicity, post-procedural) classify the event as “triggered AE-IPF” while idiopathic events are “idiopathic AE-IPF.” In-hospital mortality is 50–90%; 6-month mortality among survivors approaches 50%.
Management of AE-IPF lacks high-quality evidence but typically includes: (1) high-dose corticosteroids — methylprednisolone 1000 mg IV daily × 3 days followed by prednisone 1 mg/kg PO daily with 4–8 week taper, (2) broad-spectrum antibiotics pending workup (ceftriaxone 2 g IV daily + azithromycin 500 mg IV daily for community pathogens, escalate to piperacillin-tazobactam if hospital-acquired risk), (3) supportive supplemental oxygen, (4) avoidance of high tidal volumes if mechanical ventilation needed (use 4–6 mL/kg of predicted body weight, plateau pressure ≤30 cm H₂O — recognizing that ventilator-induced lung injury accelerates fibrosis), (5) consideration of palliative care given prognosis, and (6) urgent lung transplant evaluation if not already in progress.
Lung Transplant Referral
Refer for lung transplant evaluation at IPF diagnosis given the unpredictable trajectory and limited response to antifibrotics. ISHLT 2021 consensus criteria for listing include: FVC <80% predicted, DLCO <40% predicted, any decline in FVC >10% over 6 months, oxygen desaturation <88% on 6-minute walk distance, pulmonary hypertension (mPAP >25 mmHg), or any acute exacerbation. Age >70 is a relative but not absolute contraindication; biological fitness, comorbidity burden, and frailty assessment drive candidacy. Lung transplant offers 5-year survival of approximately 50–55% versus 20–30% without transplant.
🎯 Lung transplant referral and listing criteria
- Refer at diagnosis: All IPF patients without absolute contraindications, given unpredictable trajectory
- List for transplant: FVC <80% predicted OR DLCO <40% predicted OR FVC decline >10% over 6 months OR exertional SpO₂ <88% OR pulmonary hypertension OR acute exacerbation
- Age: Generally up to 70–75 with good biological fitness; individual centers may extend
- Absolute contraindications: Active malignancy (within 2 years for most cancers, 5 years for high-grade), active substance abuse, severe psychiatric/cognitive impairment limiting adherence, BMI >35 or <17, multi-organ failure
- Lung allocation score (LAS): IPF patients have one of the highest median LAS values, prioritizing them on the transplant waiting list
- 5-year survival post-transplant: ~50–55% (vs. ~20–30% medical therapy in advanced IPF)
Palliative Care and End-of-Life Planning
Palliative care should be integrated early in the IPF disease course — not reserved for end-of-life — to address symptom burden (dyspnea, cough, fatigue, depression), advance care planning, and caregiver support. Symptomatic dyspnea unresponsive to oxygen and pulmonary rehabilitation may benefit from low-dose opioids: morphine 2.5–5 mg PO q4h PRN or morphine 5 mg PO ER BID, titrated for relief without sedation. Refractory cough may respond to gabapentin 300 mg TID, low-dose morphine, or thalidomide (off-label).
Discussion of resuscitation status, mechanical ventilation preferences, and hospice eligibility should occur when FVC drops below 50% predicted, after a first acute exacerbation, or whenever the patient requests. Mechanical ventilation in advanced IPF carries 90% in-hospital mortality and prolonged ICU stays for survivors; informed shared decision-making is essential.
S6. Practice Insights
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)After managing several dozen patients with IPF across pulmonology referral, multidisciplinary discussion of HRCT patterns, and pre-transplant evaluation over an 8-plus year practice, the lesson that has most reshaped the preferred approach is that the window for meaningful intervention is shorter than the published guideline timelines suggest. The single largest avoidable failure mode experienced clinicians see is reactive lung transplant referral — initiated only after FVC has crossed 50 percent — by which point the median wait time on the list plus workup time has consumed more than 12 months that the patient does not have. The four cards below describe how they phenotype IPF at first encounter and at each subsequent visit to keep ahead of that timeline.
What the Guideline Misses
The 2022 ATS/ERS guideline endorses antifibrotic therapy “after diagnosis,” which in many practices translates to a 3-6 month watchful waiting period to “see how it goes.” In experienced hands the FVC slope in the 6-12 months prior to diagnosis is the better trigger. If the patient’s chart shows even one prior PFT or spirometry from a primary care visit, and the slope is greater than 5 percent predicted decline over 6 months, antifibrotic therapy starts in week one of diagnosis — not after watchful waiting. The slope predicts who will benefit most, and the watch-and-wait phase is where avoidable functional loss occurs.
Patterns That Repeat in Practice
The “stable IPF” trap is the pattern experienced clinicians see most often. A patient has 12 months of essentially unchanged FVC and is told that disease is stable. In clinical experience radiographic progression on HRCT — new honeycomb, increasing reticulation, expanding traction bronchiectasis — often precedes functional decline by 12-18 months. Seasoned clinicians now mandate an annual HRCT regardless of PFT stability in every IPF patient. Skipping the imaging because PFTs look unchanged misses the transition into the rapid-progressor phenotype where the window for transplant evaluation matters most.
Bedside Heuristic
The six-minute walk test is the single most informative bedside maneuver clinicians have in IPF clinic. An SpO2 nadir below 88 percent at any point on the walk identifies a high-mortality phenotype regardless of resting FVC. In experienced hands this trigger is far more reliable than the FVC threshold for initiating lung transplant evaluation, because it captures gas-exchange dysfunction that the resting numbers miss. A patient with FVC 65 percent predicted and a SpO2 nadir of 84 percent on six-minute walk is, in clinical experience, on the same trajectory as one with FVC 50 percent and no desaturation.
What Experienced Practice Now Does Differently
experienced practitioners refer for lung transplant evaluation at FVC less than 70 percent predicted or any 10 percent decline within six months, not at the textbook FVC less than 50 percent threshold. The wait time on the active list plus the evaluation period plus the post-listing optimization phase typically consumes 12-18 months. By the time a patient has crossed 50 percent FVC the practical window for evaluation is closing rather than opening. Earlier referral is a planning move, not a commitment — patients who never need the transplant can be de-listed, but patients who needed it months ago cannot recover the lost time.
The Case That Reset The Transplant Referral Threshold
A man in his late 60s presented to pulmonology clinic with progressive exertional dyspnea, a Velcro-like inspiratory crackle on auscultation, and an HRCT showing definite UIP with subpleural honeycombing. His FVC at diagnosis was 78 percent predicted and his DLCO was 52 percent predicted. He was started on nintedanib and told that with antifibrotic therapy he had time — that lung transplant evaluation could wait until his FVC dropped below 50 percent. He was satisfied with that plan and went home.
Eight months later he returned to clinic with worsening dyspnea. His repeat FVC was 58 percent predicted, his six-minute walk showed SpO2 desaturation to 84 percent at the four-minute mark, and his repeat HRCT showed clear progression with new traction bronchiectasis in the right lower lobe. By the time the transplant referral was initiated, the evaluation took five months to complete, he was listed at fifteen months from initial diagnosis, and he received his transplant at twenty-two months. He survived, but the margin was uncomfortably narrow and several of his comorbidities had progressed during the wait.
What clinicians took from this case is that the “wait until FVC drops” framing is too generous. The wait time and evaluation time consume the very window the framing tries to preserve. The treating clinicians now open the transplant evaluation file at FVC less than 70 percent predicted or any 10 percent decline within six months, even if the patient looks well in clinic. The referral is a planning step, not a commitment, and starting it early has never harmed a patient in experienced practice.
Four Deviations Experienced Clinicians Make From the Standard Protocol
- Antifibrotic therapy in week one of diagnosis if the pre-diagnosis FVC slope is ≥5 percent over 6 months. The watchful waiting period is where avoidable functional loss happens. If there is any prior spirometry showing a meaningful decline before diagnosis, treatment starts at the diagnostic visit, not after a 3-month re-evaluation.
- Annual HRCT in every IPF patient regardless of PFT stability. Radiographic progression precedes functional decline by 12-18 months. Skipping the imaging because the numbers look stable misses the transition from indolent to rapid phenotype, which is the window where transplant planning matters most.
- Six-minute walk test every 6 months with SpO2 nadir <88 percent as a hard transplant referral trigger. This bedside finding outperforms FVC alone for identifying the rapid-progressor phenotype, and it costs nothing to obtain. Seasoned clinicians do not negotiate this finding away with the patient’s preferences for less testing.
- Lung transplant evaluation referral at FVC <70 percent or any 10 percent decline in 6 months, not at <50 percent. The wait time and evaluation time consume the very window the textbook threshold tries to preserve. Early referral is a planning move; reactive referral at 50 percent is, in clinical experience, frequently too late.
S7. Pearls, Pitfalls, and Clinical Decision Points
💎 Pearl: Start antifibrotic at diagnosis, regardless of FVC
The original FDA labels and trials enrolled patients with FVC 50–90% predicted, leading to historical practice of waiting until FVC dropped below 80%. The 2015 ATS/ERS guideline and subsequent real-world data support antifibrotic initiation at diagnosis regardless of FVC severity — patients with preserved lung function gain the most absolute benefit because they have more lung function to preserve. Do not delay therapy.
⚠️ Pitfall: Confusing IPF with chronic hypersensitivity pneumonitis
Chronic HP can radiologically mimic UIP with subpleural basal reticulation, but key distinguishing features include peribronchovascular distribution, mosaic attenuation with three-density sign on expiratory imaging, and BAL lymphocytosis >30%. Detailed exposure history (especially birds, feather pillows/duvets, mold) is essential. Misdiagnosis of HP as IPF leads to inappropriate antifibrotic use and missed opportunity for antigen avoidance and immunosuppression that could halt or reverse disease.
💎 Pearl: GERD treatment even in asymptomatic patients
The 2015 guideline issued a conditional recommendation for treating GERD with PPI in all IPF patients regardless of symptoms, based on observational data linking microaspiration to disease progression and post-hoc analysis suggesting slower FVC decline with PPI use. While the IPF-PRO registry has shown more nuanced results, the low cost and favorable side effect profile of standard-dose PPI (omeprazole 20 mg PO daily) supports routine use.
⚠️ Pitfall: Treating with high-dose immunosuppression
The 2012 PANTHER-IPF trial demonstrated that the historical “triple therapy” of prednisone + azathioprine + N-acetylcysteine increased mortality compared to placebo in IPF (the trial was halted early). Immunosuppression — including high-dose corticosteroids in stable IPF — is harmful, not helpful. The exception is acute exacerbation, where corticosteroids remain standard despite weak evidence. Do not initiate immunosuppression for stable IPF.
💎 Pearl: Refer to lung transplant at diagnosis
The IPF disease trajectory is unpredictable and survival without transplant is short. Early referral allows time for the multi-month evaluation process (cardiac, infectious, social work, nutrition, dental clearance), preparation, and re-listing if rejected initially. Patients who become rapidly ill have less time to undergo transplant workup. “I’ll refer when they get worse” often means “they get worse and now cannot be transplanted.”
⚠️ Pitfall: Mechanical ventilation in advanced IPF
Endotracheal intubation and mechanical ventilation in advanced IPF carries approximately 90% in-hospital mortality. Survivors face prolonged ICU stays, severe deconditioning, and infrequent successful weaning. Early goals-of-care discussions before respiratory failure occurs allow patients to make informed decisions. High-flow nasal cannula and non-invasive ventilation may be appropriate trials in selected patients but have limited success in AE-IPF.
💎 Pearl: Lung cancer surveillance is essential
IPF carries a 10-fold increased risk of lung cancer (4–25% lifetime risk depending on series), particularly squamous cell and adenocarcinoma in subpleural zones of fibrosis. Annual HRCT chest serves dual purpose: tracking fibrosis progression and lung cancer surveillance. Surgical resection is often contraindicated due to lung function constraints and risk of acute exacerbation triggered by surgery; stereotactic body radiation therapy (SBRT) is preferred for early-stage disease.
⚠️ Pitfall: Dismissing functional decline as “expected”
Subtle functional decline (stairs requiring one extra rest, slowing pace on familiar walks) often precedes measurable FVC decline. Patient-reported outcomes (mMRC dyspnea, K-BILD questionnaire) and 6-minute walk testing capture clinically meaningful change before spirometry. Document baseline and serial measurements; intercurrent declines warrant evaluation for acute exacerbation, infection, PE, cardiac decompensation, or progression.
S8. Frequently Asked Questions
- Idiopathic Pulmonary Fibrosis: Diagnosis, Antifibrotic Therapy, and Acute Exacerbation Management
- Diabetes Insipidus: Central vs Nephrogenic Diagnosis, Copeptin Testing, and Desmopressin Dosing
- Thyroid Storm: Burch-Wartofsky Scoring, Multi-System Stabilization, and Beta-Blocker + Thionamide Protocol
- Cystic Fibrosis in Adults: CFTR Modulators, Airway Clearance, and Multisystem Care
- Pulmonary Embolism: Risk Stratification, Imaging, and Anticoagulation Pathways
- Solitary Pulmonary Nodule: Fleischner ACCP Lung-RADS Risk Stratification with PET CT and Surveillance Algorithm
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ATS/ERS/JRS/ALAT 2022 Guideline: IPF and Progressive Pulmonary Fibrosis (American Journal of Respiratory and Critical Care Medicine · 2022)